Darzalex 400mg Injection (Daratumumab) – Complete Product Description

Darzalex 400mg Injection (Daratumumab) is a prescription cancer medicine manufactured by Janssen. It contains daratumumab, a human monoclonal antibody used as part of treatment regimens for multiple myeloma and, in certain approved settings, light-chain (AL) amyloidosis.

Daratumumab is a targeted immunotherapy that binds to CD38, a protein highly expressed on multiple myeloma cells. By binding to CD38, daratumumab can help destroy malignant plasma cells through several immune-mediated mechanisms.

Darzalex may be used alone or in combination with other medicines, depending on the patient’s diagnosis, previous treatments, disease stage and applicable treatment protocol.

The product listed here is Darzalex 400mg Injection, manufactured by Janssen, with a pack size of 1 injection/vial. It is administered by intravenous infusion by a qualified healthcare professional.

Darzalex 400mg Injection – Product Information

Brand Name: Darzalex
Active Ingredient: Daratumumab
Strength: 400mg
Presentation: 400mg/20mL
Dosage Form: Solution/concentrate for intravenous infusion
Route of Administration: Intravenous (IV) infusion
Manufacturer: Janssen
Pack Size: 1 injection/vial
Drug Class: Monoclonal antibody
Therapeutic Class: Antineoplastic / Cancer immunotherapy
Target: CD38
Prescription Status: Prescription medicine

What Is Darzalex 400mg Injection Used For?

Darzalex contains daratumumab and is primarily used in the treatment of multiple myeloma, a cancer of plasma cells in the bone marrow.

Depending on the patient’s disease and treatment history, daratumumab may be used:

• As monotherapy in selected patients with multiple myeloma
• In combination with bortezomib and dexamethasone
• In combination with lenalidomide and dexamethasone
• In combination with pomalidomide and dexamethasone
• In combination with carfilzomib and dexamethasone
• In combination with other approved multiple myeloma treatment regimens
• In selected patients with systemic AL amyloidosis

The exact regimen depends on the patient’s condition, prior treatment, transplant eligibility and the prescribing oncologist’s treatment plan.

Darzalex for Multiple Myeloma

Multiple myeloma is a blood cancer in which abnormal plasma cells accumulate in the bone marrow and produce abnormal immunoglobulins.

These malignant plasma cells can interfere with normal blood-cell production and may contribute to:

• Anemia
• Bone damage
• Kidney problems
• High calcium levels
• Increased susceptibility to infections

Daratumumab targets CD38 on malignant plasma cells and helps the immune system eliminate these abnormal cells.

Darzalex can be incorporated into different treatment combinations to improve disease control in appropriately selected patients.

Darzalex for AL Amyloidosis

Daratumumab may also be used in combination with other medicines for selected adults with light-chain (AL) amyloidosis.

In AL amyloidosis, abnormal plasma cells produce light-chain proteins that can accumulate in organs and cause organ dysfunction.

By targeting CD38-positive plasma cells, daratumumab can reduce the production of abnormal light chains in appropriate patients.

How Does Darzalex (Daratumumab) Work?

Darzalex contains daratumumab, a human monoclonal antibody that targets CD38.

CD38 is a surface protein found at high levels on multiple myeloma cells and other abnormal plasma cells.

After binding to CD38, daratumumab can promote the destruction of cancer cells through several mechanisms, including:

• Complement-dependent cytotoxicity
• Antibody-dependent cellular cytotoxicity
• Antibody-dependent cellular phagocytosis
• Direct apoptosis-related effects
• Modulation of immune-cell activity

Through these mechanisms, Darzalex helps reduce the number of abnormal plasma cells.

Darzalex 400mg Dose and Administration

Darzalex 400mg is administered by intravenous infusion.

The exact dose depends on the approved treatment regimen.

For many adult multiple myeloma regimens, daratumumab is administered at 16mg/kg, meaning the total amount required is calculated according to the patient’s body weight.

The 400mg vial therefore represents a specific product presentation and may be used together with additional vials to achieve the prescribed dose.

Daratumumab dosing frequency may change during treatment. Depending on the regimen, infusions may initially be given more frequently and later at longer intervals.

The treating oncologist determines:

• The total dose
• Infusion schedule
• Combination medicines
• Treatment duration
• Need for treatment interruption or modification

Darzalex must not be self-administered.

It should be prepared and administered by qualified healthcare professionals in a suitable medical facility.

Premedication Before Darzalex Infusion

Because daratumumab can cause infusion-related reactions, patients are generally given appropriate pre-infusion medications.

Depending on the treatment protocol, premedication may include:

• Corticosteroids
• Antihistamines
• Antipyretics

Additional medicines may be prescribed after infusion to reduce the risk of delayed respiratory reactions.

The healthcare team will monitor the patient during and after the infusion.

Common Side Effects of Darzalex 400mg

Like all medicines, Darzalex can cause side effects.

Commonly reported adverse effects may include:

• Infusion-related reactions
• Fatigue
• Weakness
• Nausea
• Diarrhea
• Constipation
• Back pain
• Muscle spasms
• Cough
• Shortness of breath
• Upper respiratory tract infection
• Fever
• Headache
• Peripheral edema
• Insomnia

The frequency and severity of adverse effects may vary depending on whether Darzalex is administered alone or in combination with other medicines.

Serious Side Effects of Darzalex

Infusion-Related Reactions

Infusion-related reactions are an important potential adverse effect of intravenous daratumumab.

Symptoms may include:

• Nasal congestion
• Cough
• Shortness of breath
• Wheezing
• Chills
• Fever
• Nausea
• Headache
• Chest discomfort
• Changes in blood pressure

Most reactions occur during or shortly after the infusion, but delayed reactions can also occur.

Patients are monitored during administration, and the infusion may be slowed or stopped if a significant reaction develops.

Infections

Daratumumab can increase the risk of infections, particularly when used with other immunosuppressive or antimyeloma medicines.

Patients should promptly report:

• Fever
• Persistent cough
• Sore throat
• Burning during urination
• Other signs of infection

Low Blood Cell Counts

Darzalex-containing treatment regimens may cause:

• Neutropenia
• Anemia
• Thrombocytopenia

Regular blood tests may be required during treatment.

Darzalex and Blood Transfusions

Daratumumab can interfere with blood compatibility testing.

Because daratumumab binds to CD38 expressed on red blood cells, it can cause a positive indirect antiglobulin test and may interfere with compatibility testing for blood transfusions.

Patients receiving Darzalex should inform their healthcare providers and blood bank that they are receiving daratumumab.

A baseline blood type and screening may be performed before treatment begins.

Darzalex and Hepatitis B Virus

Daratumumab-containing treatment may be associated with hepatitis B virus reactivation in susceptible patients.

Healthcare professionals may test patients for hepatitis B infection before starting treatment.

Patients with current or previous hepatitis B infection may require additional monitoring during and after treatment.

Precautions Before Using Darzalex 400mg

Tell your doctor before receiving Darzalex if you have:

• A history of serious infusion reactions
• Respiratory disease
• Asthma or chronic obstructive pulmonary disease
• A current infection
• Previous or current hepatitis B infection
• Blood disorders
• Kidney problems
• Liver problems
• A history of severe allergic reactions

Tell your healthcare provider about all medicines and supplements you are taking.

Darzalex During Pregnancy

Women who are pregnant or planning pregnancy should discuss treatment with their healthcare provider before receiving Darzalex.

The potential risks and benefits of daratumumab during pregnancy should be carefully evaluated by the treating specialist.

Women who can become pregnant should discuss appropriate contraception during treatment and for the recommended period after treatment.

Darzalex and Breastfeeding

It is not known whether daratumumab passes into human breast milk.

Because of the potential for adverse effects in a breastfed infant, patients should discuss breastfeeding with their healthcare provider before starting treatment.

The treating physician will determine whether breastfeeding should be discontinued during therapy.

Darzalex 400mg Storage

Darzalex is a biological medicine requiring appropriate temperature-controlled storage.

Store according to the manufacturer’s recommended conditions and protect the product from light.

Do not freeze or shake Darzalex.

The medicine should remain in its original packaging until preparation.

Dilution and preparation for intravenous infusion must be performed using appropriate sterile procedures by qualified healthcare professionals.

Darzalex 400mg Injection Price in Pakistan

The Darzalex 400mg Injection price in Pakistan may vary depending on availability, supplier, import costs, exchange rates and prevailing market conditions.

For the latest Darzalex 400mg price in Pakistan, customers can contact MedicineWalyDost.com to check current availability and pricing.

As Darzalex is a specialized oncology biological medicine, prices may fluctuate. Confirm the latest price before ordering.

Why Choose Darzalex 400mg Injection?

Darzalex contains daratumumab, a targeted monoclonal antibody that specifically binds to CD38 and plays an important role in modern multiple myeloma treatment.

It can be incorporated into several treatment regimens, either alone or with other medicines, depending on the patient’s clinical condition.

The Janssen Darzalex 400mg Injection presentation is supplied as a 400mg/20mL vial and listed here with a pack size of 1 injection/vial.

Because daratumumab can cause infusion-related reactions and affect blood compatibility testing, treatment should always be managed by an experienced oncology team.

Frequently Asked Questions About Darzalex 400mg

What is Darzalex 400mg Injection?

Darzalex 400mg Injection is a prescription cancer medicine containing daratumumab, a monoclonal antibody that targets CD38.

What is the generic name of Darzalex?

The generic name is daratumumab.

Who manufactures Darzalex 400mg?

The manufacturer of the product listed here is Janssen.

What is the pack size of Darzalex 400mg?

The pack size is 1 injection/vial.

What is Darzalex used for?

Darzalex is primarily used for multiple myeloma and is also used in selected treatment regimens for AL amyloidosis.

How is Darzalex 400mg administered?

Darzalex is administered by intravenous infusion by a qualified healthcare professional.

Is 400mg the complete Darzalex dose?

Not necessarily. Many adult treatment regimens use a weight-based dose of 16mg/kg, so more than one 400mg vial may be required to achieve the prescribed dose.

Does Darzalex cause infusion reactions?

Yes. Infusion-related reactions are common with intravenous daratumumab. Appropriate premedication and monitoring are used to reduce and manage this risk.

Can Darzalex affect blood transfusions?

Yes. Daratumumab can interfere with certain blood compatibility tests. Patients should inform healthcare providers and blood banks that they are receiving Darzalex before a blood transfusion.

Can Darzalex be used with other medicines?

Yes. Daratumumab is frequently used in combination with other multiple myeloma medicines. The specific combination depends on the patient’s diagnosis and treatment history.

Is Darzalex chemotherapy?

Darzalex is not conventional chemotherapy. It is a targeted monoclonal antibody and cancer immunotherapy that targets CD38-positive cells.

Can Darzalex 400mg be purchased without a prescription?

Darzalex is a specialized prescription oncology medicine and should only be used under the supervision of a qualified hematologist or oncologist.

Order Darzalex 400mg Injection in Pakistan

Looking for Darzalex 400mg Injection (Daratumumab) by Janssen in Pakistan?

MedicineWalyDost.com provides access to specialized prescription medicines and oncology products. Contact us to check the latest Darzalex 400mg price, availability and ordering information.

Before ordering, confirm the brand, strength, active ingredient, manufacturer, pack size and prescription requirements with your doctor or pharmacist.

Order Darzalex 400mg Injection from MedicineWalyDost.com and contact us today for current availability and pricing.

Important Medical Disclaimer

Darzalex 400mg Injection is a prescription biological oncology medicine. This product description is intended for educational and e-commerce purposes only and does not replace professional medical advice. Daratumumab can cause serious infusion-related reactions, infections and other adverse effects and requires specialist supervision. Do not start, stop or modify treatment without consulting your treating healthcare professional.

---